Willett Advisors LLC manages the philanthropic assets of Michael R. Bloomberg, including the assets of Bloomberg Philanthropies. The firm seeks long-term capital appreciation through a diversified investment portfolio across public markets, hedge funds, private equity and credit, real assets, and direct investments.
50% of their portfolio is in Biotech & Life Sciences. Deal activity increased 200% year-over-year (3 deals in the last 12 months). Average disclosed round size is $124.1M (across 16 rounds with reported amounts).
Portfolio
14
Fund Size
—
Top Stage
Series B
Last 12 Mo
3
Team
Neil Shah
Managing Director
Rodolfo Chou
Managing Director, Public Markets
Charanya Rangamannar
Director, Real Assets
Dylan Gorman
Director
Georges Hermes
Director
Peter Crews
Director, Real Assets
Andrew Mulderry
Chief Investment Officer
Peter Krow
Investment Management
Steven Rattner
Chairman and CEO
Portfolio Breakdown
Stage Distribution
Sector Distribution
Investment Activity
Portfolio
| Company | Round | Amount | Date |
|---|---|---|---|
 Kinaset Therapeutics | Series B | $103M | Jan 2026 |
| KKinaset | Series B | $103M | Jan 2026 |
 AAVantgarde Bio | Series B | — | Nov 2025 |
 Neurona Therapeutics | Unknown | $102M | Apr 2025 |
 Neurona | Series A | $102M | Jan 2025 |
 Remix Therapeutics | Series C | $60M | Jan 2024 |
 Cellares | Series C | $255M | Aug 2023 |
 Carmot Therapeutics | Series E | $150M | May 2023 |
 Disc Medicine | Series B | $90M | Sep 2021 |
 TraceLink | Series D | $93M | Aug 2018 |
| FFinch Therapeutics Group | Growth | — | — |
| FFinch Therapeutics Group | Series C | $53M | — |
| AAntares Therapeutics | Series A | $177M | — |
 Aavantgarde | Series B | $141M | — |
 Kinaset Therapeutics | Series B | $103M | — |
| Carmot Therapeutics | Series D | $160M | — |
| Cellares | Series D | $257M | — |
| FFinch Therapeutics Group | Series B | $36M | — |
Top Co-Investors
Last updated: 7 October 2026